The aim of the research group is the creation of 3D models (microorgan/ organoids) constructed using samples obtained from patients, both biopsy samples and samples collected with non-invasive techniques (exhaled breath condensate, induced sputum, blood samples). These models would allow the identification of disease biosensors and the definition of a targeted drug therapy for each patient, customizing both the drug to be used and the most effective doses (drug toxicity and efficacy tests, precision therapies and precision medicine). This system offers innovative aspects for analytical laboratory activities, favoring integrated diagnostic applications for pharmacology / precision medicine that concern both basic and clinical medicine. In this way, we will be obtained an innovative laboratory support for the physician, improving patient management with important socio-economic consequences. In view of the above innovative aspects, the method could be highly competitive in the pharmaceutical and diagnostic industry.
The competitive advantages compared to any other competitors are linked to a proven experience in the results interpretation obtained which have given rise to scientific dissemination through publications in journals with international editorial committees.
The advantage of performing these specific laboratory tests is the ability to identify the patient's phenotype, the most effective drug and the best dose to identify an intelligent drug therapy with important economic and social consequences.
The realization of specific laboratory tests could affect industries specialized in diagnostics and pharmacology, which affect public health and individual patient care. Such activities could implement industrial resources. The advantage over any competitor is our consolidated experience in the biomedical sector with national and international expertise in studies on biological samples of patients and experimental models.
Italy, Europe